FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine and aims at blood coagulation inhibition in a human patient. It involves applying betrixaban or its pharmaceutically acceptable salts. Total daily dose makes 0.01 to 2.0 mg/kg.
EFFECT: group of inventions has an effect on thrombin formation and anti-Xa activity inhibition.
6 tbl, 12 dwg, 9 ex, 11 cl
| Title | Year | Author | Number |
|---|---|---|---|
| N-GUANIDINOALKYLAMINES, PRODUCTION, USES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | 2000 |
|
RU2253651C2 |
| DERIVATIVES OF (THIO)UREA INHIBITING VIIa FACTOR, METHOD FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITION | 2001 |
|
RU2286337C2 |
| FACTOR Xa INHIBITOR SALT, METHOD FOR MAKING IT, BASED PHARMACEUTICAL COMPOSITION, TABLET, CAPSULE AND LOZENGE CONSISTING OF THIS COMPOSITION, METHOD FOR TREATING THROMBOSIS AND METHOD FOR INHIBITING BLOOD SAMPLE COAGULATION | 2006 |
|
RU2440986C2 |
| COMPOSITIONS AND METHODS FOR HAEMOSTASIS MODULATION | 2011 |
|
RU2570547C2 |
| FXa INHIBITORS WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AS P4 SUBUNIT, METHODS OF OBTAINING THEREOF AND THEIR PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES | 2009 |
|
RU2468024C2 |
| INHIBITORS OF XA FACTOR | 1995 |
|
RU2152954C1 |
| THROMBIN INHIBITING DNA-APTAMERS AND METHOD OF STRUCTURE STABILISATION | 2009 |
|
RU2429293C1 |
| OXAZOLIDINONES FOR TREATING AND/OR PREVENTING CARDIAC EMBARRASSMENTS | 2008 |
|
RU2494740C2 |
| PURINE DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT | 1997 |
|
RU2191778C2 |
| DIAZEPANE DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND INHIBITOR OF BLOOD COAGULATION ACTIVATED FACTOR X | 2001 |
|
RU2257381C2 |
